Freestone Grove Partners LP Makes New $12.14 Million Investment in Revolution Medicines, Inc. $RVMD

Key Points

• Freestone Grove Partners acquired 64,813 Revolution Medicines shares worth approximately $12.14 million in the second quarter. Institutional investors collectively own 94.34% of RVMD.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $193.28; several firms recently raised their targets, including HC Wainwright to $280 and Evercore to $320.
• Insiders have been selling shares, including the CFO and a director, while the company reported a quarterly loss of $3.06 per share versus the expected $2.04. Revolution Medicines remains unprofitable and analysts forecast a full-year loss of $8.82 per share.

Freestone Grove Partners LP purchased a new position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 64,813 shares of the company's stock, valued at approximately $12,138,000.

Several other hedge funds also recently made changes to their positions in RVMD. Vanguard Group Inc. lifted its holdings in Revolution Medicines by 6.7% during the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company's stock worth $1,331,739,000 after purchasing an additional 1,056,792 shares in the last quarter. State of Wyoming purchased a new position in Revolution Medicines during the 2nd quarter valued at about $1,769,000. Handelsbanken Fonder AB increased its position in shares of Revolution Medicines by 243.6% during the second quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company's stock valued at $39,755,000 after buying an additional 150,500 shares during the period. Eagle Health Investments LP bought a new stake in shares of Revolution Medicines during the fourth quarter valued at about $9,231,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Revolution Medicines during the second quarter valued at about $37,547,000. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Revolution Medicines in a research report on Friday, July 17th. TD Cowen raised shares of Revolution Medicines to a "strong-buy" rating in a report on Monday. Piper Sandler increased their target price on shares of Revolution Medicines to $172.00 and gave the stock an "overweight" rating in a research note on Thursday, May 7th. Evercore reissued an "outperform" rating and issued a $320.00 price target on shares of Revolution Medicines in a report on Thursday. Finally, HC Wainwright boosted their price target on shares of Revolution Medicines from $195.00 to $280.00 and gave the company a "buy" rating in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $193.28.

Insider Activity

In related news, CFO Jack Anders sold 20,000 shares of the firm's stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the transaction, the chief financial officer directly owned 123,269 shares of the company's stock, valued at approximately $20,749,870.77. This trade represents a 13.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Sushil Patel sold 5,580 shares of the business's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $187.99, for a total value of $1,048,984.20. Following the completion of the sale, the director owned 21,656 shares of the company's stock, valued at $4,071,111.44. The trade was a 20.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is owned by insiders.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Revolution Medicines Stock Performance

NASDAQ RVMD opened at $221.15 on Friday. Revolution Medicines, Inc. has a 52-week low of $37.56 and a 52-week high of $224.31. The company has a fifty day moving average of $192.43 and a 200-day moving average of $148.17. The company has a market capitalization of $47.40 billion, a P/E ratio of -25.07 and a beta of 1.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the company earned ($1.31) earnings per share. As a group, equities research analysts predict that Revolution Medicines, Inc. will post -8.82 EPS for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source